Medical oncologist at Gustave Roussy & PhD student at Université Paris-Saclay Precision medicine for lung cancer✨ Cellular therapy and innovative treatments ☀️
Paris, France
Joined January 2022
- Tweets74
- Following352
- Followers438
- Likes668
Arianna Marinello, MD retweeted
Be ready to screen MTAP loss in all pts with advanced NSCLC, regardless of driver.
@mihaela_aldea shows incidence, highest in ALK/RET/EGFR/ROS1.
AMG193 paved the way at #ESMO24.
BMS-986504 confirms druggability: 29% ORR + many durable SD (slide @CharuAggarwalMD). #WCLC25
Arianna Marinello, MD retweeted
Italian National Team at #WCLC2025 @AriMarinel @RobertoFerrara_ @Max_Cani @Gmazzaschi90 @pecci_federica1 @doctordegio @CarloGenova5 and many others 🇮🇹🍕
Excited to share our article out in @JAMAOnc
The first to report the expression of membrane targets in RET+ NSCLC in a wide international cohort
Have a look:
jamanetwork.com/journals/jam…
@GustaveRoussy @CarisLife
🚨 New insights in #RETpositive #LungCancer:
RET+ NSCLC often express MET & TROP2, moderately HER3 & EGFR, and rarely HER2.
➡️ Multiple membrane targets may co-exist
🧬 Dynamic changes post-treatment — fresh biopsy recommended
💡 Supports ADC & bispecific antibody trials
#JamaOncol @RETpositive @AriMarinel @GustaveRoussy @CarisLife
jamanetwork.com/journals/jam…
Proud of being part of these amazing research group in @GustaveRoussy, made of great professionals and mentors
Great "CLUB031" meeting this morning with our young talents and @BenjaminBesseMD to discuss progress on the translational studies they are brilliantly carrying out at @GustaveRoussy ! What a pleasure to accompany them in their career in thoracic oncology...@ClaudiaParisi18
So grateful for the great opportunity to participate to @IASLC Academy this year!
Arianna Marinello, MD retweeted
The use of liquid biopsy can allow a better selection of NSCLC patients candidate to IO or Chemo-IO. Very interesting data, further confirming the prognostic role of Tumor Fraction at baseline @isliquidbiopsy @ChristianRolfo
Congrats @FilippoDallOlio and team!
Can #liquidbiopsy (#tumorfraction) help identify #NSCLC patients who respond better to chemo-immunotherapy vs those who benefit from the low toxicity of single-agent immunotherapy? Pushing boundaries in #precisiononcology @GustaveRoussy
@FoundationATCG @BenjaminBesseMD @myESMO
Arianna Marinello, MD retweeted
What happens in the tumor and in the host when tumor burden increases? Could we use tMTV to decide when intensify the treatment in aNSCLC? We tried to answer these questions in our multicentric effort
@BenjaminBesseMD @GustaveRoussy – at Vorst, België
ICB or chemo-ICB in PD-L1≥50% advanced NSCLC? Metabolic tumor volume (tMTV) assessed by 18F FDG petscan can guide you.
High tMTV lesions might have a different biology and be better candidate to chemo-ICB. @FilippoDallOlio
aacrjournals.org/clincancerr…
Arianna Marinello, MD retweeted
🏆 Un grand bravo à Dr Antonio di Meglio, Dr Cédric Pobel, Dr Adèle Bonato, Dr Adrien Rousseau, Dr Arianna Marinello pour le prix du "Merit Travel Grant" de l'#ESMO24.
Arianna Marinello, MD retweeted
🔹@GustaveRoussy à l'#ESMO24
Les experts de l'institut sont présents pour leurs sessions poster. 💪
Mora Guardanamie, Arianna Marinello et Mihaela Aldea, Adrien Rousseau et Filippo Dall’Olio. ⤵
Arianna Marinello, MD retweeted
From the largest RET-registry, a huge multicentric effort, @AriMarinel presents outcomes to inhibitors/chemo in RET+ advanced NSCLC according to histological subtypes. @GustaveRoussy @myESMO
The time for a practice-changing trial in locally advanced SCLC has come!
🏆
In the ADRIATIC trial: significant OS benefit with durvalumab consolidation versus placebo after CTRT:
- 55.9 versus 33.4 months OS at the first interim analysis
#ASCO24
One-minute applause and standing ovation for the PFS LAURA in today plenary session at #ASCO24
🏆 Consolidation therapy with osimertinib in unresectable stage III NSCLC improves PFS with an outstanding HR of 0.16
What a great time to cure lung cancer patients!
Interesting work presented by @mihaela_aldea at @AACR Annual Meeting 2024 ✨✨✨
@GustaveRoussy and @lifen_fr collaborate help data collection and facilitate clinical research
Come and have a look at her poster in section #36 board #29
#AACR
Great work on blood based NGS in head and neck carcinoma presented at @AACR Annual Meeting by @FilippoDallOlio from @GustaveRoussy
Board #10 section #40
Arianna Marinello, MD retweeted
We know how will be the next Research Building @GustaveRoussy (Q1 2027)
32 000 m2 , 60 research teams in 15 Centers, 15 core facilities, 1400 staff. Each floor will include 10 teams of biology that will surround Data Science / Epidemiology teams. We are welcoming new teams !
Arianna Marinello, MD retweeted
Ceralasertib (ATR kinase inhibitor) for 7 days + durvalumab q4w: a promising combo post chemo-IO in pts with advanced NSCLC! nature.com/articles/s41591-0…. Benefit seen in all comers, including ATM altered NSCLC & manageable safety. Currently tested vs docetaxel in the trial Latify.
Arianna Marinello, MD retweeted
ESMO Guideline: Oncogene-Addicted #mNSCLC. Developed due 2 advances in biomarker identificatn & targeted therapies; updated recommendatns & tx algorithms on new & clinically relevant biomarker identificatn, targeting & adv disease managemt.ow.ly/b89e50QkVFs
@Annals_Oncology
Arianna Marinello, MD retweeted
We’ll start 2024 with this ttx algorithm for NSCLC🫁including non-metastatic NSCLC
Pending Qx💡:
✏️Will ADC overcome docetaxel? 📛
✏️ADC 2n L for oncogenic-driven? 🎉
✏️Perioperative vs Induction?🥊
✏️Adjuvant RET TKI?🧬
✏️Academic trials for ↗️ / ↘️ ttx
And more!! @oncoalert
Arianna Marinello, MD retweeted
🔹 @GustaveRoussy à l'#ESMO2023 🔹
Découvrez les posters des experts de l'institut à @myESMO 👇
🔸 Dr Isabelle Borget
🔸 Dr Kristi Beshiri
🔸 Dr @AriMarinel
Incredibily amazing discussion conducted by @BenjaminBesseMDtk conclude this exciting plenary session on #NSCLC with rare alterations ->
The (un)necessary trials
So proud of being part of his motivated team! – at Madrid, Spain
